Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer |
| |
Authors: | Timur Mitin William U. Shipley Jason A. Efstathiou Niall M. Heney Donald S. Kaufman Richard J. Lee Anthony L. Zietman |
| |
Affiliation: | 1. Harvard Medical School, Massachusetts General Hospital, Department of Radiation Oncology, Boston, MA, 02114, USA 2. Harvard Medical School, Massachusetts General Hospital, Department of Urology, Boston, MA, USA 3. Harvard Medical School, Massachusetts General Hospital, Department of Hematology and Oncology, Boston, MA, USA
|
| |
Abstract: | During the past 25 years, prospective clinical trials have established that bladder preservation therapy for select patients with muscle-invasive bladder cancer is a safe and effective alternative to an immediate cystectomy. Cisplatin-based chemoradiation is the most well-studied and accepted component of trimodality therapy; however, other systemic agents have recently been shown effective in combination with radiation therapy, increasing the range of options to allow for better personalization of care. In this review, the most recent advances in the field of bladder-preserving trimodality therapy are presented, and future directions for improving the outcomes are outlined. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|